Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes

Diabetologia

Volumn 42, Issue 12, 1999, Pages 1433-1438

  Ebeling, P ^a   Teppo, A M ^b   Koistinen, H A ^b   Viikari, J ^b   Ronnemaa T ^b   Nissen M ^b   Bergkulla, S ^b   Salmela, P ^b   Saltevo, J ^b   Koivisto, V A ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b NONE

Author keywords

Complement protein C3; Hyperglycaemia; Inflammation; Serum amyloid A; Troglitazone; Type II diabetes

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMYLOID A PROTEIN; C REACTIVE PROTEIN; CERULOPLASMIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; TROGLITAZONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ACUTE-PHASE PROTEINS; AGED; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CHROMANS; COMPLEMENT C3; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; MIDDLE AGED; OROSOMUCOID; PLACEBOS; SERUM AMYLOID A PROTEIN; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0033434124     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051315     Document Type: Article

References (32)

1. 1. McMillan DE (1989) Increased levels of acute-phase serum proteins in diabetes. Metabolism 38: 1042-1046
2. 2. Pickup JC, Mattock MB, Chusney GD, Burt D (1997) NIDDM as a disease of the innate immune system: association of acutephase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40: 1286-1292
3. 3. Alexander RW (1994) Inflammation and coronary artery disease. N Engl J Med 331: 468-469
4. 4. Spiegelman BM, Flier JS (1996) Adipogenesis and obesity: rounding out the big picture. Cell 87: 377-389
5. 5. Koistinen HA, Koivisto VA, Ebeling P (1998) Serum complement protein C3 is a marker of insulin resistance, which is related to obesity, but not to hyperglycemia. Diabetes 47 [Suppl 1] A311
6. 6. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J (1994) Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331: 1188-1193
7. 7. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM (1992) Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM patients. Diabetes Care 15: 193-203
8. 8. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270: 12953-12956
9. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 83: 803-812
10. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83: 813-819
11. 11. Willson TM, Cobb JE, Cowan DJ et al. (1996) The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39: 665-668
12. 12. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391: 79-82
13. 13. Jiang C, Ting AT, Seed B (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82-86
14. 14. Murase K, Odaka H, Suzuki M, Tayuki N, Ikeda H (1998) Pioglitazone time-dependently reduces tumour necrosis factor-α level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia 41: 257-264
15. 15. Spiegelman BM (1998) PPARγ in monocytes: less pain, any gain? Cell 93: 153-155
16. 16. Ebeling P, Tuominen JA, Bourey R, Koranyi L, Koivisto VA (1995) Athletes with IDDM exhibit impaired metabolic control and increased lipid utilization with no increase in insulin sensitivity. Diabetes 44: 471-477
17. 17. Honkanen E, Grönhagen-Riska C, Teppo A-M, Maury CPJ, Meri S (1991) Acute-phase proteins during hemodialysis: correlations with serum interleukin-1β levels and different dialysis membranes. Nephron 57: 283-287
18. 18. Andersen JK, Mole JE (1982) Large scale isolation and partial primary structure of human plasma amyloid P-component. Ann N Y Acad Sci 389: 216-234
19. 19. Maury CPJ (1985) Comparative study of serum amyloid A protein and C-reactive protein in disease. Clin Sci 68: 233-238
20. 20. Baumann H, Morella KK, Wong GHW (1993) TNF-α, IL-1β and hepatocyte growth factor cooperate in stimulating specific acute-phase plasma protein genes in rat hepatoma cells. J Immunol 151: 4248-4257
21. 21. Thiel S, Vorup-Jensen T, Stover CM et al. (1997) A second serine protease associated with mannan-binding lectin that activates complement. Nature 386: 506-510
22. 22. Choy LN, Rosen BS, Spiegelman BM (1992) Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 267: 12736-12741
23. 23. Cianflone K, Roncari DAK, Maslowska M, Baldo A, Forden J, Sniderman AD (1994) Adipsin / acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis. Biochemistry 33: 9489-9495
24. 24. Steel DM, Whitehead AS (1994) The major acute-phase reactants; C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 15: 81-88
25. 25. Andersen O, Vilsgaard Ravn K, Juul Sørensen I, Jonson G, Holm Nielsen E, Svehag S-E (1997) Serum amyloid P component binds to influenza A virus haemagglutinin and inhibits the virus infection in vitro. Scand J Immunol 46: 331-337
26. 26. Pomeroy C, Mitchell J, Eckert E, Raymond N, Crosby R, Dalmasso AP (1997) Effect of body weight and caloric restriction on serum complement proteins, including Factor D/adipsin: studies in anorexia nervosa and obesity. Clin Exp Immunol 108: 507-515
27. 27. Hotamisligil GS, Arner P, Atkinson RL, Spiegelman BM (1997) Differential regulation of the p80 tumour necrosis factor receptor in human obesity and insulin resistance. Diabetes 46: 451-455
28. 28. Jacobson JM, Greenspan JS, Spritzler J et al. (1997) Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 336: 1487-1493
29. 29. Krantz S, Stelter F, Lober M, Rjasanowski I, Michaelis D, Buske B (1988) Complement component 3 (C3) and diabetes mellitus. Exp Clin Endocrinol 92: 287-296
30. 30. Figueredo A, Ibarra JL, Bagazgoitia J et al. (1993) Plasma C3 d levels and ischemic heart disease in type II diabetes. Diabetes Care 16: 445-449
31. 31. Mollnes TE (1985) Quantification of the C3 d split products of human complement by a sensitive enzyme-linked immunosorbent assay. Scand J Immunol 21: 607-613
32. 32. Hawkins M, Barzilai N, Liu R, Hu M, Chen W, Rossetti L (1997) Role of the glucosamine pathway in fat-induced insulin resistance. J Clin Invest 99: 2173-2182